Literature DB >> 3763262

Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism.

C Holtzman, W E Slazyk, J F Cordero, W H Hannon.   

Abstract

We conducted a structured telephone survey of state public health laboratory directors of neonatal screening programs to determine the extent of the problem of missed cases of phenylketonuria (PKU) and congenital hypothyroidism. A total of 76 missed cases were reported--43 PKU and 33 congenital hypothyroidism. We looked at the following characteristics of the missed cases: the stage at which the miss occurred, which included specimen collection, laboratory procedures, or follow-up; the size of the program; the type of screening program; the age of the infant at the time of screening; and any legal action that resulted from the miss. The 76 missed cases probably represent an underascertainment of the true number, yet we believe that our data provide an overview of some of the problems associated with mass neonatal screening. There was one missed case of PKU for every 70 cases detected, and one missed case of congenital hypothyroidism for every 120 cases detected; in other words, two congenital hypothyroidism cases were missed for every 1 million infants screened. Regarding the stage of screening in which the miss occurred, 14% occurred during specimen collection, 45% during the laboratory procedures stage, 16% during follow-up, 11% were the result of biologic variation, and in 14% the stage could not be identified. We conclude that neonatal screening programs have been highly successful but that there may be additional safeguards to be developed, tested, and implemented when practical.

Entities:  

Mesh:

Year:  1986        PMID: 3763262

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  12 in total

1.  Clinical and laboratory data in a sample of Greek children with autism spectrum disorders.

Authors:  Athina Ververi; Efthymia Vargiami; Vassiliki Papadopoulou; Dimitrios Tryfonas; Dimitrios I Zafeiriou
Journal:  J Autism Dev Disord       Date:  2012-07

2.  Newborn screening in North America.

Authors:  Bradford L Therrell; John Adams
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

3.  Quality performance of newborn screening systems: strategies for improvement.

Authors:  D Webster
Journal:  J Inherit Metab Dis       Date:  2007-08-14       Impact factor: 4.982

4.  A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations.

Authors:  I B Sardharwalla; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Pacific northwest regional newborn screening: a paradigm of prevention.

Authors:  J M Tuerck; N R Buist
Journal:  J Med Syst       Date:  1988-04       Impact factor: 4.460

6.  Computerized surveillance of errors in newborn screening practice.

Authors:  J M Tuerck; N R Buist; M R Skeels; R S Miyahira; P G Beach
Journal:  Am J Public Health       Date:  1987-12       Impact factor: 9.308

Review 7.  Computerized tracking for newborn screening and follow-up: a review.

Authors:  F J Meaney
Journal:  J Med Syst       Date:  1988-04       Impact factor: 4.460

8.  Survey of neonatal screening for primary hypothyroidism in England, Wales, and Northern Ireland 1982-4.

Authors:  D B Grant; I Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-14

9.  Screening for congenital hypothyroidism in France. Misdiagnosed cases: collaborative study of screening centres in France.

Authors:  J Leger
Journal:  Eur J Pediatr       Date:  1990-06       Impact factor: 3.183

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.